Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.

International journal of molecular sciences - 30 Aug 2024

Leifheit Malia E, Johnson Gunnar, Kuzel Timothy M, Schneider Jeffrey R, Barker Edward, Yun Hyun D, Ustun Celalettin, Goldufsky Josef W, Gupta Kajal, Marzo Amanda L

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML represent a challenging clinical scenario characterized by a high rate of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The advent of FLT3 tyrosine kinase inhibitors (TKIs), such as midostaurin and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazines

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 39273395
DOI: 10.3390/ijms25179448
PMCID: PMC11394928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.PMID 39273395Read ↗

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.Semantic proximity Read ↗

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.Semantic proximity Read ↗

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

A review of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib: potent targeting of FLT3 mutations in AML.Semantic proximity Read ↗

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Semantic proximity Read ↗

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsSemantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukemia.Semantic proximity Read ↗

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.